A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 39-44

  Kawahara, Akihiko ^a   Taira, Tomoki ^a   Azuma, Koichi ^b   Tominaga, Masaki ^c   Hattori, Satoshi ^d   Kawahara, Mayuko ^c   Abe, Hideyuki ^a   Yamaguchi, Tomohiko ^a   Akiba, Jun ^b   Takamori, Shinzo ^b   Hayashi, Akihiro ^c   Kage, Masayoshi ^a  

^a KURUME UNIVERSITY HOSPITAL   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Shin Koga Hospital   (Japan)

^d KURUME UNIVERSITY   (Japan)

Author keywords

Activating EGFR mutations; Diagnostic algorithm; EGFR mutation specific antibody; Immunohisto cytochemistry; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LOCKED NUCLEIC ACID; MUTANT PROTEIN; PEPTIDE NUCLEIC ACID; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALGORITHM; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY DEVICE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PEPTIDE NUCLEIC ACID LOCKED NUCLEIC ACID POLYMERASE CHAIN REACTION CLAMP ASSAY; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ALGORITHMS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866160573     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.002     Document Type: Article

References (18)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell-lung cancer. J Clin Oncol 2003, 21(12):2237-2246.
2. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl Med 2004, 350(21):2129-2139.
3. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
4. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "neversmokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
5. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028.
6. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176.
7. Kitamura A., Hosoda W., Sasaki E., Mitsudomi T., Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16(13):3349-3355.
8. Kato Y., Peled N., Wynes M.W., Yoshida K., Pardo M., Mascaux C., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5(10):1551-1558.
9. Nakamura H., Mochizuki A., Shinmyo T., Ando K., Kurimoto N., Yokote K., et al. Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res 2010, 30(12):5233-5237.
10. Simonetti S., Molina M.A., Queralt C., de Aguirre I., Mayo C., Bertran-Alamillo J., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 18(8):135-142.
11. Dimou A., Agarwal S., Anagnostou V., Viray H., Christensen S., Gould Rothberg B., et al. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am J Pathol 2011, 179(2):580-589.
12. Kozu Y., Tsuta K., Kohno T., Sekine I., Yoshida A., Watanabe S., et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 2011, 73(1):45-50.
13. Wu S.G., Chang Y.L., Lin J.W., Wu C.T., Chen H.Y., Tsai M.F., et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One 2011, 6(8):e23303.
14. Kawahara A., Yamamoto C., Nakashima K., Azuma K., Hattori S., Kashihara M., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16(12):3163-3170.
15. Kawahara A., Azuma K., Sumi A., Taira T., Nakashima K., Aikawa E., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011, 74(1):35-40.
16. Azuma K., Okamoto I., Kawahara A., Taira T., Nakashima K., Hattori S., et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol 2012, 7(1):122-127.
17. Didelot A., Le Corre D., Luscan A., Cazes A., Pallier K., Emile J.F., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 2012, 92(3):275-280.
18. Aikawa E., Kawahara A., Hattori S., Yamaguchi T., Abe H., Taira T., et al. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol 2011, 119(5):335-345.